Close menu




June 1st, 2023 | 08:45 CEST

JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

  • Mining
  • phosphate
  • photovoltaics
  • Biotechnology
Photo credits: pixabay.com

The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: JINKOSOLAR ADR/4 DL-00002 | US47759T1007 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , FIRST PHOSPHATE CORP | CA33611D1033

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    First Phosphate: Newsflow can drive the share price

    The US government will strongly promote domestic battery production. As a supplier of an important raw material, First Phosphate will benefit from this. In Quebec, Canada (Saguenay-Lac-St-Jean region), the Company owns over 15 areas totalling 1,500 sq km with very distinct phosphate deposits, ranging from exploration sites to PEA development projects. According to the Company, it is pure magmatic anorthosite phosphate rock. Using advanced phosphate processing technology from partner Prayon, it is expected to process about 90% of phosphate concentrate production into ESG-compliant products.

    A few days ago, a major update on company development was published. First Phosphate's shares have only been listed on the stock exchanges in Canada and Germany since the first quarter of 2023. In addition, around CAD 2.3 million was raised through a capital increase, of which around 20% came from management. Financing is thus secured and investors can look forward to a lively news flow in the further course of the year. The final results of the drilling program carried out at the end of 2022 are to be published. Drilling is then scheduled to start again in the summer. In a pilot project, First Phosphate is working with its partner SGS Quebec on separating apatite, ilmenite and magnetite. If it succeeds in marketing three minerals at the same time in the future, this could enable significantly higher margins. Another pilot project is underway with Prayon. Based on the phosphate concentrate already mined, purified phosphoric acid will be produced in battery quality so that future customers from North America can convince themselves of the product quality.

    JinkoSolar: Trouble in the US

    JinkoSolar has a vertically integrated value chain: from silicon ingots, wafers and cells to modules. The Chinese photovoltaic group has recently published several announcements. Among other things, it was announced that the 56% share in Xinjiang Jinko Solar Co. will be sold. Jinko will receive around USD 622 million for this. The buyer is said to be a consortium around a fund close to the government. Xinjiang had made a profit of USD 22 million in 2022. In the first quarter of 2023, the profit was already around USD 20 million. With the sale, Jinko wants to increase production efficiency and optimize the plant mix.

    A cooperation with Antaisolar is expected to contribute to the group's further growth. Antaisolar specializes in mounting systems for photovoltaic plants. Both companies have implemented several joint projects in different countries since last year. Therefore, they now want to cooperate more closely worldwide. The strategic cooperation agreement provides for the exchange of projects, technologies, employees and other areas.

    In order to consolidate its position as the world's largest photovoltaic group, Jinko is also expanding its locations. A major new investment program has been approved. It provides for the construction of a new site for silicon wafers, solar cells and solar modules in the Chinese province of Shanxi. An annual production capacity of 56 GW is to be built in four expansion stages. Jinko wants to invest around USD 8 billion in this.

    But there was not only positive news to report. According to US media, federal officials raided a JinkoSolar site in the United States. It is not yet known exactly why. However, government subsidy programs were put on hold for the time being. Actually, Jinko wants to expand the site significantly in order to profit from the solar boom in the US. The crackdown can be seen as part of the tensions between China and the US. Again and again, there are small pinpricks such as selective trade restrictions, tariffs and the like. This may also contribute to the fact that JinkoSolar's share price has practically halved since July 2022, while the solar industry as a whole has performed positively. For example, the share price of SMA Solar, the German manufacturer of inverters, has risen by over 50% in the current year alone.

    BioNTech: EU reduces order

    Now we are changing sectors because something is also happening at the German biotech company BioNTech. The EU will buy less Corona vaccine from Pfizer and BioNTech than originally planned. According to Reuters, all parties involved have reportedly agreed to this. Given the current Corona situation, this is not surprising, but it is nevertheless likely to put further pressure on the BioNTech share, which is already struggling. After all, the vaccine is the Mainz-based company's major source of revenue. The product pipeline is full, and so is the cash register, but the share price continues to be determined by Corona news. Previously, a new variant in China led to a slight rebound in the share price. The World Health Organization has recommended updating vaccination protection against the Corona variant XBB.1.5, for example, with a monovalent vaccine. BioNTech then reported that it could quickly adapt the vaccine. In addition, the BioNTech management had explained at the annual general meeting that they were still expecting regular revenues from the Corona vaccine. However, the stock market is not likely to see any significant gains at the moment.


    Investors in First Phosphate can look forward to a lively newsflow in the further course of the year. If this is positive, the share should be able to regain its March level of CAD 1 quickly. The share is currently trading below CAD 0.50. At JinkoSolar, the tensions between the US and China are acting as a brake on the share. At BioNTech, there is simply a lack of positive news, such as study results from the pipeline. In addition, the biotech sector is not the focus of investors at the moment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on March 4th, 2024 | 07:15 CET

    Kraken Energy, RWE, Plug Power - Is Germany reconsidering its nuclear phase-out?

    • Mining
    • Energy
    • renewableenergies
    • nuclear
    • Uranium

    Calls for a U-turn on the nuclear energy issue are getting louder in Germany. Above all, the AfD, the CDU/CSU, and the FDP, as members of the traffic light government, are calling for a resumption of nuclear power generation. In Europe, Germany's energy policy has already caused considerable head-shaking. Nuclear power can shoulder the base load, does not produce CO2 emissions and is cheaper and less volatile than renewable energies. Many countries agree on one thing: we need to move away from fossil fuels. In the Czech Republic, plans are underway to build 4 new nuclear power plants, and in Poland, the Netherlands and Sweden, there is no longer interest in phasing out nuclear power. It will be interesting to see how Germany's struggle for energy develops.

    Read

    Commented by André Will-Laudien on March 4th, 2024 | 07:00 CET

    1200% with artificial intelligence, 100% with Bitcoin, and now comes Gold! Barrick, Desert Gold, Aixtron and Super Micro

    • Mining
    • Gold
    • AI
    • Bitcoin

    The stock market keeps rising - this is indicated by the ever-new highs of prominent indices such as the NASDAQ 100 or the DAX 40 index. However, a closer look reveals some inconsistencies. For example, only 7% of all traded stocks are currently reaching new highs, while over 60% of all listed stocks are falling. In short, global liquidity is aggregated in just a few blockbuster stocks worldwide, while the rest are being left behind. Such bubbles occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. No one knows when it will happen again, but the party will likely last a little longer. Gold and Silver have been trending sideways at a high level for the past 3 years, but the yellow metal showed the first signs of life last week. What should investors look out for now?

    Read

    Commented by Juliane Zielonka on March 1st, 2024 | 17:05 CET

    Cardiol Therapeutics, Bayer, Coinbase - Which share will generate profits in the long term?

    • Biotechnology
    • Pharma
    • crypto

    The world of pharmaceuticals and life sciences is characterized by precisely documented studies in clinical research. If an active ingredient makes it to approval, there is the potential for a blockbuster worth billions. Cardiol Therapeutics has an active ingredient in the second phase of clinical research for the treatment of heart disease in people under 35 years of age. This active ingredient can also restore the quality of life of 26 million people worldwide who suffer from heart failure. Bayer continues to clean up the unresolved issues left behind by the former CEO. Did the weedkiller RoundUp® from the Monsanto deal possibly lead to improper treatment due to a lack of consumer protection information? The five-figure lawsuits still pending against Roundup are dampening the share's profit prospects. The situation is currently quite different in the cryptocurrency market. Bitcoin is outperforming everyone, and the Coinbase share is benefiting from it. Which investment generates profits in the long term?

    Read